IDO1 and cancer: Therefore, IDO inhibitors are considered promising candidates for cancer immunotherapy and a few are under preclinical and clinical exploration, such as indoximod (D-1-MT, NLG-8189), Navoximod (NLG-919), Epacadostat (INCB024360), PI-3065, and PF-06840003 (EOS200271).